Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer

[1]  E. Pukkala,et al.  Statins and cancer: A systematic review and meta-analysis. , 2008, European journal of cancer.

[2]  F. Pontén,et al.  HMG‐CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors , 2008, International journal of cancer.

[3]  M. Freeman,et al.  Do the cholesterol-lowering properties of statins affect cancer risk? , 2008, Trends in Endocrinology & Metabolism.

[4]  L. Esserman,et al.  Estrogen Receptor–Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users , 2008, Cancer Epidemiology Biomarkers & Prevention.

[5]  Jung-Hsin Lin,et al.  Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. , 2008, Cancer research.

[6]  K. Jirström,et al.  Oestrogen receptors α and β show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer , 2007, Journal of Clinical Pathology.

[7]  L. Habel,et al.  Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors , 2008, Breast Cancer Research and Treatment.

[8]  D. Miglioretti,et al.  Statin Use and Breast Cancer Risk in a Large Population-Based Setting , 2007, Cancer Epidemiology Biomarkers & Prevention.

[9]  Anindya Dutta,et al.  Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells , 2006, Molecular Cancer Therapeutics.

[10]  E. Petricoin,et al.  Breast cancer growth prevention by statins. , 2006, Cancer research.

[11]  S. Bonovas,et al.  Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Welch,et al.  Statins and the Risk of Colorectal Cancer , 2005, The New England journal of medicine.

[13]  G. Thorgeirsson,et al.  Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) , 2004, The Lancet.

[14]  H. Mo,et al.  Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention , 2004, Experimental biology and medicine.

[15]  Henk-Jan Guchelaar,et al.  The risk of cancer in users of statins. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Liao.  Isoprenoids as mediators of the biological effects of statins. , 2002, The Journal of clinical investigation.

[17]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[18]  W C Willett,et al.  Aspirin and the risk of colorectal cancer in women. , 1995, The New England journal of medicine.

[19]  G. Berglund,et al.  Design and feasibility , 1993 .

[20]  G. Berglund,et al.  The Malmo Diet and Cancer Study. Design and feasibility. , 1993, Journal of internal medicine.

[21]  O. Larsson,et al.  Requirement for mevalonate in the control of proliferation of human breast cancer cells. , 1992, Anticancer research.